Showing 18,641 - 18,660 results of 19,549 for search '(( significant ((nn decrease) OR (a decrease)) ) OR ( significantly increased decrease ))', query time: 0.77s Refine Results
  1. 18641

    Image 3_Comparative microbiome analysis of paired mucosal and fecal samples in Korean colorectal cancer patients.tif by Younggwang Kim (21562529)

    Published 2025
    “…Background<p>Colorectal cancer (CRC) is increasingly linked to gut microbiome dysbiosis. However, few studies have examined tumor-associated microbial dynamics in Korean CRC patients using both mucosal and fecal samples.…”
  2. 18642

    Image 2_Comparative microbiome analysis of paired mucosal and fecal samples in Korean colorectal cancer patients.tif by Younggwang Kim (21562529)

    Published 2025
    “…Background<p>Colorectal cancer (CRC) is increasingly linked to gut microbiome dysbiosis. However, few studies have examined tumor-associated microbial dynamics in Korean CRC patients using both mucosal and fecal samples.…”
  3. 18643

    Table 2_Comparative microbiome analysis of paired mucosal and fecal samples in Korean colorectal cancer patients.docx by Younggwang Kim (21562529)

    Published 2025
    “…Background<p>Colorectal cancer (CRC) is increasingly linked to gut microbiome dysbiosis. However, few studies have examined tumor-associated microbial dynamics in Korean CRC patients using both mucosal and fecal samples.…”
  4. 18644

    Table 3_Comparative microbiome analysis of paired mucosal and fecal samples in Korean colorectal cancer patients.docx by Younggwang Kim (21562529)

    Published 2025
    “…Background<p>Colorectal cancer (CRC) is increasingly linked to gut microbiome dysbiosis. However, few studies have examined tumor-associated microbial dynamics in Korean CRC patients using both mucosal and fecal samples.…”
  5. 18645

    Table 4_Comparative microbiome analysis of paired mucosal and fecal samples in Korean colorectal cancer patients.docx by Younggwang Kim (21562529)

    Published 2025
    “…Background<p>Colorectal cancer (CRC) is increasingly linked to gut microbiome dysbiosis. However, few studies have examined tumor-associated microbial dynamics in Korean CRC patients using both mucosal and fecal samples.…”
  6. 18646

    Health Risks of Low-Dose Dietary Exposure to Triphenyl Phosphate and Diphenyl Phosphate in Mice: Insights from the Gut–Liver Axis by Jing Cao (287196)

    Published 2025
    “…TPHP intake affected the levels of short-chain fatty acids and bile acids in the gut, enhancing the production of 29 medium- and long-chain fatty acids in the liver by 3.72-fold and significantly increasing hepatic lipid and cholesterol levels. …”
  7. 18647

    Point Application Therapy Targeting Feishu, Pishu and Shenshu Attenuates Asthma by Suppressing Autophagy and the AMPK-mTOR Signalling Pathway by Yutong Jin (2873837)

    Published 2025
    “…The treatment additionally decreased expression levels of mTOR, LC3, NF-κB and TGF-β1 while increasing AMPK content. …”
  8. 18648

    Table 1_Biological characterization of novel Escherichia coli O157:H7 phages and their bacteriostatic effects in milk and pork.xlsx by Qinghai Ren (20686166)

    Published 2025
    “…Notably, vB_EcoP_SD2 displayed a latent period of 10 min, a burst period of 80 min, and a burst volume of 80 PFU per cell, while vB_EcoP_SD6 had a burst volume of 10 PFU per cell. …”
  9. 18649

    Data Sheet 1_Biological characterization of novel Escherichia coli O157:H7 phages and their bacteriostatic effects in milk and pork.pdf by Qinghai Ren (20686166)

    Published 2025
    “…Notably, vB_EcoP_SD2 displayed a latent period of 10 min, a burst period of 80 min, and a burst volume of 80 PFU per cell, while vB_EcoP_SD6 had a burst volume of 10 PFU per cell. …”
  10. 18650

    Table 2_Biological characterization of novel Escherichia coli O157:H7 phages and their bacteriostatic effects in milk and pork.xlsx by Qinghai Ren (20686166)

    Published 2025
    “…Notably, vB_EcoP_SD2 displayed a latent period of 10 min, a burst period of 80 min, and a burst volume of 80 PFU per cell, while vB_EcoP_SD6 had a burst volume of 10 PFU per cell. …”
  11. 18651

    Table 1_The relationship between the ratio of non-high-density lipoprotein cholesterol to high-density lipoprotein cholesterol (NHHR) and both MASLD and advanced liver fibrosis: ev... by Juyi Li (8996117)

    Published 2025
    “…Elevated NHHR levels in the Q2 and Q3 groups remained significantly linked to a decreased risk of advanced liver fibrosis, with odds ratios of 0.61 (95% CI 0.40–0.94, P = 0.03) and 0.64 (95% CI 0.47–0.89, P = 0.01), respectively. …”
  12. 18652

    Table 5_The relationship between the ratio of non-high-density lipoprotein cholesterol to high-density lipoprotein cholesterol (NHHR) and both MASLD and advanced liver fibrosis: ev... by Juyi Li (8996117)

    Published 2025
    “…Elevated NHHR levels in the Q2 and Q3 groups remained significantly linked to a decreased risk of advanced liver fibrosis, with odds ratios of 0.61 (95% CI 0.40–0.94, P = 0.03) and 0.64 (95% CI 0.47–0.89, P = 0.01), respectively. …”
  13. 18653

    Data Sheet 1_The role of ATP6V0D2 in breast cancer: associations with prognosis, immune characteristics, and TNBC progression.docx by Jingyu Zhang (256203)

    Published 2024
    “…Objective<p>Researches have identified ATPase H+ transporting V0 subunit d2 (ATP6V0D2) as a significant factor in various cancers. However, its prognostic value in breast cancer (BRCA) and its biological role in BRCA cells remain unclear.…”
  14. 18654

    Table 4_The relationship between the ratio of non-high-density lipoprotein cholesterol to high-density lipoprotein cholesterol (NHHR) and both MASLD and advanced liver fibrosis: ev... by Juyi Li (8996117)

    Published 2025
    “…Elevated NHHR levels in the Q2 and Q3 groups remained significantly linked to a decreased risk of advanced liver fibrosis, with odds ratios of 0.61 (95% CI 0.40–0.94, P = 0.03) and 0.64 (95% CI 0.47–0.89, P = 0.01), respectively. …”
  15. 18655

    Table 2_The relationship between the ratio of non-high-density lipoprotein cholesterol to high-density lipoprotein cholesterol (NHHR) and both MASLD and advanced liver fibrosis: ev... by Juyi Li (8996117)

    Published 2025
    “…Elevated NHHR levels in the Q2 and Q3 groups remained significantly linked to a decreased risk of advanced liver fibrosis, with odds ratios of 0.61 (95% CI 0.40–0.94, P = 0.03) and 0.64 (95% CI 0.47–0.89, P = 0.01), respectively. …”
  16. 18656

    Data Sheet 1_The multivalent passive immune-protective vaccines of egg yolk immunoglobulin Y derived from live or inactivated Pseudomonas anguilliseptica against aquaculture pathog... by Pan Cui (5726669)

    Published 2025
    “…Furthermore, the structures of the kidney, spleen, and intestinal tissues were intact, and the expression of p53 and γH2A.X decreased in the kidney.</p>Conclusion<p>L-PA-IgY and I-PA-IgY can resist multiple bacterial infections and have immunoprotective effects with no significant differences. …”
  17. 18657

    Table 3_The relationship between the ratio of non-high-density lipoprotein cholesterol to high-density lipoprotein cholesterol (NHHR) and both MASLD and advanced liver fibrosis: ev... by Juyi Li (8996117)

    Published 2025
    “…Elevated NHHR levels in the Q2 and Q3 groups remained significantly linked to a decreased risk of advanced liver fibrosis, with odds ratios of 0.61 (95% CI 0.40–0.94, P = 0.03) and 0.64 (95% CI 0.47–0.89, P = 0.01), respectively. …”
  18. 18658

    Supplementary Material for: Minimal Change Disease and Focal Segmental Glomerulosclerosis are associated with good kidney prognosis and Thrombotic Microangiopathy with poor kidney... by Neves P.D.M.M. (20408168)

    Published 2024
    “…The time between COVID-19 diagnosis and kidney biopsy was 30 (15-60) days. Most patients had decreased kidney function at diagnosis, 43.5% required dialysis upon diagnosis, 77.6% received immunosuppression, and 2/3 achieved a clinical remission. …”
  19. 18659

    Table 2_Outcomes after therapeutic SBE-ERCP for choledochojejunal/hepaticojejunal anastomotic stenosis after bile duct injury.docx by Yijun Shu (3456728)

    Published 2025
    “…Background<p>Choledochojejunal/hepaticojejunal anastomotic stenosis (CJS/HJS) is significant clinical problem associated with decreased survival postsurgery. …”
  20. 18660

    Table 3_Outcomes after therapeutic SBE-ERCP for choledochojejunal/hepaticojejunal anastomotic stenosis after bile duct injury.docx by Yijun Shu (3456728)

    Published 2025
    “…Background<p>Choledochojejunal/hepaticojejunal anastomotic stenosis (CJS/HJS) is significant clinical problem associated with decreased survival postsurgery. …”